Objective: To measure effects of fish oil supplements on lipoprotein subclasses by nuclear magnetic resonance (NMR) in subjects with type II diabetes and relate them to insulin sensitivity. Design: Two-armed, parallel, placebo-controlled, randomized. Subjects: Normotriglyceridemic subjects with type II diabetes without insulin treatment were given either fish oil (n ¼ 12, median intake 5.9 g/day total n-3 fatty acids (FA) (1.8 g 20:5n-3, 3.0 g 22:6n-3)) or corn oil (n ¼ 14, 8.5 g/day 18:2n-6 FA). Methods: Size and concentration of lipoproteins subclasses were measured by NMR, insulin sensitivity by hyperinsulinemic, isoglycemic clamps. Results: After 9 weeks, there were differences between those treated with fish and corn oil with respect to very low-density lipoprotein (VLDL) size (median À15 vs þ 0.6%, P ¼ 0.001), particle concentrations of large VLDL (À99 vs À4.1%, P ¼ 0.041) and small high-density lipoprotein (HDL) (À12 vs þ 10%, P ¼ 0.051). Compared with corn oil fish oil tended to increase HDL size and small low-density lipoprotein ( LDL) concentration (P ¼ 0.063 and 0.068, respectively, for differences between groups). There was no effect on oxidized LDL. Insulin sensitivity (glucose utilization) decreased in the fish oil group compared with the corn oil group (P ¼ 0.049). The decrease in insulin sensitivity did not correlate with the effects on lipoprotein subclasses. Conclusions: A high intake of n-3 FA exerts effects on several lipoprotein subclasses without obvious influence from changes in insulin sensitivity.
Introduction
Evidence indicates that marine intake of n-3 fatty acids (FA) has several, potentially beneficial, effects on cardiovascular disease (Connor, 2000; Harris, 2004) . The mechanisms for some effects are known, whereas those for others are unknown. One important effect is prevention of ventricular fibrillation and sudden death (Connor, 2000) . Such effects are probably related to physicochemical changes in membranes of excitable cells and are achieved by small doses (approximately 1 g/day) of n-3 FA.
Other effects of marine n-3 FA may be linked to effects on lipids and lipoproteins. Such effects are of special interest in subjects with increased risk of cardiovascular disease, such as subjects with type II diabetes (Steinmetz, 2003) . Lipoprotein subclasses rather than very low-density lipoprotein (VLDL), low-density lipoprotein (LDL) or high-density lipoprotein (HDL) cholesterol may be linked to cardiovascular disease. Small dense LDL, which is part of the dyslipoproteinemia in type II diabetes (Steinmetz, 2003) , is considered to be the most atherogenic among subclasses (Packard, 2006) . However, also other subclasses have been suggested to be atherogenic (i.e. large, less dense VLDL) or less cardioprotective (i.e. small, dense HDL) (Freedman et al., 1998) ; also these dyslipidemic features are part of the lipoprotein subclass profile in type II diabetes (Syvänne and Taskinen, 1997) . It is therefore important to investigate effects of n-3 FA on subclasses and size of lipoproteins in subjects with type II diabetes (Syvänne and Taskinen, 1997; Julius, 2003; Steinmetz, 2003) . However, such investigations in diabetes by standard methods (ultracentrifugation, gradient gel electrophoresis) have so far given sparse and diverging results (Luo et al., 1998; Patti et al., 1999; Petersen et al., 2002) . Measurements using nuclear magnetic resonance (NMR) relate to the severity of cardiovascular disease (Freedman et al., 1998) and could provide needed details of lipoprotein size and subclasses (Otvos, 2002) .
Observational studies using NMR in subjects with insulin resistance and subjects with type II diabetes have shown associations between insulin resistance on the one hand and higher particle concentrations of lipoprotein subclasses as large VLDL, small LDL and small HDL as well as lower concentrations of large LDL and large HDL, lowered size of HDL and LDL and increased VLDL size on the other (Garvey et al., 2003; Goff et al., 2005) . From these results, it was suggested that insulin resistance could be the cause of this profile of lipoproteins. However, randomized trials on subjects with type II diabetes are needed to rigorously test the notion of a cause-effect relationship. Such trials would test for effects of potentially lipid modifying interventions such as n-3 FA.
Previously we performed a 9-week study in which we investigated effects of n-3 FA supplements by fish oil on insulin sensitivity (by hyperinsulinemic isoglycemic clamps) in subjects with type II diabetes (Mostad et al., 2006) . The results showed that the n-3 FA supplement reduced insulin sensitivity and moderately increased blood glucose concentrations. On this occasion, we wished to assess whether n-3 FA supplementation (a) affected lipoprotein subclasses as measured by NMR and, if so (b) whether there existed a cause-effect relationship between n-3 FA effects on lipoproteins on the one hand and effects on glucose utilization as measured by the clamps, on the other. Purposely, we excluded subjects with overt hypertriglyceridemia in order to avoid possible secondary effects of the well-documented lowering effect by n-3 FA on hypertriglyceridemia. Oxidized LDL is a strong predictor of cardiovascular disease (Meisinger et al., 2005) and is further found to correlate positively with the concentration of small, dense LDL particles in subjects with type II diabetes (Scheffer et al., 2003) . Therefore, we also included measurements of oxidized LDL.
Methods
Inclusion and exclusion criteria Subjects between 40 and 75 years of age were recruited through advertisements in the local newspaper. Type II diabetes was defined by clinical criteria and by the absence of antibodies to glutamic acid decarboxylase. Participants had never used supplements with fish oil or marine n-3 FA or discontinued such supplement for X6 months before baseline. Exclusion criteria were insulin treatment, hypertriglyceridemia (42.2 mmol/l), proliferative retinopathy, pregnancy or lactation, allergy to fish or citrus, smoking, alcoholism and congestive heart failure or other serious diseases affecting the ability of the subject to participate.
General design
The study had a parallel design. Subjects were screened on the basis of their medical history and a physical examination. The period from inclusion to baseline (week 0) varied between 1 and 12 months. Randomization was performed by the method of minimization (Pocock and Simon, 1975) , with the factors body mass index (BMI), HbA 1c , the use of oral hypoglycemic medication, gender, age, fasting C-peptide concentration and fatty fish intake, weighted as 4, 3, 3, 2, 2, 2 and 1, respectively (Jensen, 1991) . The intervention lasted for 9 weeks and effects were measured after 1 and 9 weeks.
Subjects
Of the 27 subjects included (13 male, 14 female subjects), 14 (six male, eight female subjects) were randomly assigned to receive corn oil and 13 (seven male, six female subjects) to receive fish oil. One subject assigned to the fish oil group left the study after 3 days of intervention because of noncompliance with the protocol. Data from this subject are excluded from all results.
Details on intervention
The intervention consisted of a prescribed daily intake of 20 ml fish oil enriched with n-3 FA, given as liquid. Control subjects were prescribed equal amounts of corn oil. Both oil preparations were distributed in identical bottles, flavored with lemon and supplemented with vitamin E. The subjects also ingested 60 mg/day vitamin C together with the oil. The composition of the two types of oil has been published elsewhere (Mostad et al., 2006) . The subjects received disposable premarked 20-ml dose cups, and took the daily dosage of oils and vitamins at home. The oil bottles were weighed at baseline and at the end of the study. The weight difference was used to calculate the amount ingested during the study period, using r ¼ 0.925 as the oil density. The remaining vitamin C tablets were collected and counted. Successful blinding was documented by a post study survey and compliance by analyzing the FA in plasma phospholipids (Mostad et al., 2006) .
Ethics
The local ethics committee approved the study protocol. All participants gave written informed consent.
Blood sampling and tests
Fasting blood samples were taken at baseline and after 1 and 9 weeks of intervention. On the same days we measured stimulated insulin secretion (C-peptide glucagon test) and insulin sensitivity (isoglycemic clamp). Details on test methods and test results have been reported elsewhere (Mostad et al., 2006) . Before each test day, the subjects fasted 12 h (and abstained 24 h from alcohol). They were told not to engage in strenuous exercise on the day before sampling. In the morning on test days, subjects travelled for o1 h to arrive at the hospital at 0800 h. For each individual subject, we used the same weekdays for sampling at baseline and after 1 and 9 weeks of intervention.
Antropometric measurements
Height (in cm) was measured to one decimal point. Weight (in kg) was measured to one decimal point with subjects wearing indoor clothing and without shoes. Waist circumference was measured with the subject in underwear, with shoulders relaxed and arms hanging alongside.
Diet
Intake of food and beverages was recorded with the use of frequency questionnaires at baseline and at week 9. Results were computed with regard to intake of energy and nutrients, as described (Mostad et al., 2006) . The food database was mainly based on the official Norwegian Food Table (Rimestad et al., 1995) .
Processing of blood samples
Blood for analyzing plasma lipids and lipoprotein subclasses were drawn into serum tubes with and without gel, respectively. The samples from tubes without gel were also used for analyzing oxidized LDL. All serum samples were centrifuged (2000 g, 12 min, 201C) and either analyzed immediately (glucose, HbA 1c , triglycerides, total cholesterol, LDL and HDL cholesterol) or kept at À801C for later analyses (lipoprotein subclasses, oxidized LDL).
Standard assays
Serum glucose, HbA 1c , triglyceride, total cholesterol and HDL cholesterol in fresh samples were determined by standard laboratory techniques. LDL cholesterol was calculated by the Friedewald formula (Friedewald et al., 1972) . Triglycerides, total, LDL and HDL cholesterol were also calculated in the frozen samples by NMR. Based on the assumption that a fixed relationship exists between the NMR signal amplitude and cholesterol/triglyceride concentration for each subclass, the methods' software converts the signal amplitudes into concentration units of cholesterol or triglycerides (mg/dl or mmol/l) by use of reference values from separation and quantification of cholesterol and triglycerides by standard methods (Otvos, 2002) .
Oxidized LDL Circulating oxidized LDL was determined by an oxidized LDL competitive enzyme-linked immunoabsorbent assay (Mercodia AB, Uppsala, Sweden). A monoclonal antibody (4E6) against a conformational epitope in the ApoB-100 moiety of LDL was used (Holvoet et al., 1998 (Holvoet et al., , 2001 ). The interassay coefficient variation was p7%.
Lipoprotein subclasses
Frozen serum was shipped to LipoScience Inc. (Raleigh, NC, USA) to measure lipoprotein subclass profiles by NMR spectroscopy. The methodology has been reported in detail (Otvos et al., 1992 (Otvos et al., , 2002 . In brief, each lipoprotein subclass is quantified using the NMR signals, which differ in frequency and shape depending on the diameter of the lipoprotein particles. The individual signals are derived from the total recorded signal using data from previously modelled reference lipoprotein subclasses. The intensity of each signal is proportional to the quantity of the subclass, which is reported in particle concentration units (nmol/l for VLDL and LDL and mmol/l for HDL) or lipid-mass concentration (mmol/l). The NMR spectroscopy reported three VLDL subclasses (large (60-200 nm), medium (35-60 nm) and small (27-35 nm) VLDL), four LDL subclasses (IDL (23-27 nm), large (21.2-23.0 nm), medium small (19.8-21.2 nm) and very small (18-19.8 nm) LDL) and three HDL subclasses (large (8.8-13 nm), medium (8.2-8.8 nm) and small (7.3-8.2 nm) HDL). Mean VLDL, LDL and HDL particle sizes (nm diameter) were computed as the sum of the diameters of the individual sub-populations multiplied by their relative mass percentages as estimated from the amplitudes of their methyl NMR signals. According to LipoScience Inc., the coefficients of variation for the mean particle sizes were 2% or less and for the particle concentrations of total VLDL, LDL and total HDL were 4% or less; whereas, the coefficients of variation of the individual subclasses were less than 10% with two exceptions: IDL and medium HDL (27%).
When the known HDL subclasses 2b, 2a, 3a, 3b, 3c quantified by gradient gel electrophoresis are compared with NMR measurements, 2b þ 2a equal large HDL, 3a equals medium HDL and 3b þ 3c equal small HDL (Otvos, 2002) . However, it is noteworthy that the IDL and LDL subclass diameters are uniformly 5 nm smaller than estimates based on gradient gel electrophoresis measurements.
Insulin sensitivity
Insulin sensitivity was measured at baseline and after 1 and 9 weeks by isoglycemic hyperinsulinemic clamps as described (Mostad et al., 2006) . The results of glucose utilization during clamps (glucose disposal rate, GDR) were expressed in mg/min/kg lean body mass (LBM).
Statistical analysis
Results are given as median values and interquartile ranges (IQR, the distance between the 75th and 25th percentiles). Median values were preferred for variables where skewness of data was detected or suspected, as for the lipoprotein size and concentration of subclasses. Statistical analyses were performed with SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). Normality was checked by visually inspecting Q-Q Plots. The variables of lipoprotein size and lipoprotein subclasses were log transformed to achieve normality. Baseline data between groups were compared using MannWhitney's test (Tables 1 and 2 ). Time Â treatment interaction was analyzed by repeated measures analysis of variance (ANOVA) (Figures 1-4) . If the P-value for Mauchly's test of sphericity was X0.05, the method assuming sphericity was used; otherwise, the Greenhouse-Geisser method was used. In cases where baseline variables differed between groups, analysis of covariance (ANCOVA) was used (Vickers and Altman, 2001) , that is, regression analyses with the 9-week measurement as dependent variable, and baseline measurement and group as covariates. Spearman's correlation coefficient (r) was used for bivariate correlations. P-values p0.05 (two-sided) were considered significant. Power calculations were based on the primary outcomes (glucose utilization) of the main study, presented elsewhere (Mostad et al., 2006) .
Results

Baseline variables
Age, duration of diabetes, anthropometric variables and blood pressure did not differ between groups at baseline. Neither did plasma lipids or metabolic variables except for fasting C-peptide, the concentration of which was lower in the corn oil group (Mostad et al., 2006;  Table 1 ). Lipid lowering medication (statins) was used by two subjects in the corn oil group and two subjects in the fish oil group. The statin medication was continued throughout the study. Other medications, including antidiabetic ones (Metformin alone or in combination with Glipizide or Glimepiride or Glipizide or Glimepiride alone), did not differ between groups and were not changed during the study (Mostad et al., 2006) . Five subjects in the corn oil group and seven in the fish oil group did not use antidiabetic medication. Self-reported data on diet indicated no difference between groups in total energy intake at baseline (Table 1) . The relative contribution of energy from protein, fat, carbohydrate, n-6 FA and n-3 FA did not differ between groups, neither did the dietary n-6/n-3 ratio (Table 1) . There were no differences in dietary intake of any individual FA (Mostad et al., 2006) .
Total cholesterol and triglycerides, determined in fresh serum by standard laboratory techniques, did not differ between groups at baseline (Table 1) . These lipid measurements correlated strongly with the same variables calculated by NMR in the frozen samples (the 0-week variables depicted in Figure 1a Baseline lipoprotein size and total particle concentrations were median 45 (10) nm and 81 (30) nmol/l for VLDL, 21 (1) nm and 1485 (668) nmol/l for LDL and 9 (1) nm and 27 (7) mmol/l for HDL, n ¼ 26. The size of lipoproteins determined by NMR did not differ between groups at baseline ( Table 2 ). The concentration of total lipoproteins or subclasses did not differ, except for lower concentration of small HDL in the corn oil group compared with the fish oil group (Table 2) . Circulating oxidized LDLs were similar between groups at baseline (40.6 (16.8) U/l in the corn oil compared with 44.8 (15.0) U/l in the fish oil group), P ¼ 0.662. Analyzing all subjects (n ¼ 26), the concentrations of oxidized LDL correlated significantly with the concentrations of both total LDL particles (r ¼ 0.609, P ¼ 0.001) and small LDL particles (r ¼ 0.487, P ¼ 0.012) but not with large LDL particles (r ¼ 0.254, P ¼ 0.210) or LDL size (r ¼ À0.159, P ¼ 0.438).
Effects of intervention Antropometric variables. Changes in body weight, BMI, waist circumference, waist-hip ratio, HbA 1c and blood pressure during intervention were minor and did not differ between groups (Mostad et al., 2006) .
Study oils and diet. The intake of oil was close to target in both groups (17.8 (2.3) ml/day in the corn group and 17.6 (2.0) ml/day in the fish oil group). This corresponds to 8.5 (1.1) g/day of linoleic acid (18:2n-6) in the corn oil group and 5.9 (0.7) g/day of total n-3 FA in the fish oil group. Total n-3 FA included 1.8 (0.2) g eicosapentaenoic acid (EPA, 20:5n-3), 0.3 (0.03) g docosapentaenoic acid ( 22:5n-3), and 3.0 (0.3) g docosahexaenoic acid (DHA, 22:6n-3). Total energy intake and the distribution of macronutrients did not differ between groups during intervention, and, except for the qualitative different FA intake through the study oils, the intake of individual FA did not change (Mostad et al., 2006) .
Lipids. There were no treatment differences between corn oil and fish oil groups with respect to total cholesterol, LDL cholesterol, HDL cholesterol or triglyceride (Figure 1a and b) .
Size and concentration of lipoprotein subclasses. There were treatment differences with respect to VLDL size both after 1 week (À2.9 (12)% in the corn oil group vs À12 (14)% in the fish oil group) and 9 weeks ( þ 0.6 (18)% vs À15 (7.5)% (Figure 2 with P-values included). Also regarding the concentration of large VLDL there were treatment differences after 1 week (À27 (154) vs À94 (51)%) and 9 weeks (4.1 (235) vs À99 (18)%) (Figure 2 ). There were no treatment differences with respect to the concentrations of total or small VLDL (Figure 2) .
With regard to total, small and very small LDLs these particle concentrations tended to be reduced in the corn oil group but increased in the fish oil group (Figure 3 with P-values included). There were no tendencies for treatment differences with respect to LDL size or the concentrations of large and medium small LDL.
There were treatment differences with respect to the particle concentrations of total HDL (Figure 4 with P-values included), that is, þ 5.2 (17)% for the corn oil group vs À2.8 (16)% for the fish oil group after 1 week and þ 4.5 (21) vs À3.3 (15)% after 9 weeks. Further, the fish oil reduced the concentration of small HDL. The concentration was þ 4.8 (32)% in the corn oil and À8.5 (12)% in the fish oil group after 1 week and þ 10 (33) vs À12 (17)% after 9 weeks (Figure 4 ). There was a tendency for a treatment difference with respect to HDL size (Figure 4 ). The concentration of large HDL did not differ between groups ( Figure 4 ). As apparent from Figure 4 and Table 2 , there were some differences between groups in the baseline values of total and small HDL. ANCOVA adjusts for possible impact of baseline differences on the magnitude of intervention effects (Vickers and Altman, 2001) . Therefore, this analysis was additionally performed on log-transformed data of the Table 2 , Mann-Whitney's test). P-values given in each plot are for time and treatment interaction based on log-transformed data, analyzed by repeated-measures ANOVA. Corn oil group (' .... '), n ¼ 14; fish oil group (m--m), n ¼ 12.
Effects of marine n-3 fatty acids on lipoprotein subclasses IL Mostad et al baseline and 9-week measurements of total and small HDL. By ANCOVA the effect by n-3 FA on total HDL was no longer significant (P ¼ 0.269), whereas the P-value for small HDL remained significant (P ¼ 0.051). The concentrations of medium VLDL, IDL and medium HDL were not affected by fish oil supplementation (P ¼ 0.433, 0.535 and 0.612 for time and treatment interactions analyzed by ANOVA, data not shown).
Oxidized LDL. There were no treatment differences with respect to circulating oxidized LDL. The change after 1 week was À0.6 (11.9) vs À5.4 (7.5) U/l and after 9 weeks 0.0 (11.3) vs À3.6 (17.9) U/l in the corn oil group compared with the fish oil group; P ¼ 0.882 for time and treatment interactions analyzed by ANOVA.
Changes in lipoprotein size and subclass concentrations in relation to change in insulin sensitivity from baseline to week 9. Our intervention with n-3 FA lowered glucose utilization during clamps (GDR) by mean 1.56 (0.75 s.e.m.) mg/min/kg LBM, P ¼ 0.049 (details by (Mostad et al., 2006) . Correlation analyses between changes in GDR and subclass changes of significance (VLDL size, large VLDL, small HDL) based on the effects in each participating individual, were performed. These analyses did not reveal any significant correlations (for VLDL size: r ¼ 0.134, P ¼ 0.513; for large VLDL: r ¼ 0.086, P ¼ 0.674; for small HDL: r ¼ 0.220, P ¼ 0.281). Correlations between changes in LDL subclasses with the change in insulin sensitivity were also nonsignificant: for total LDL: r ¼ À0.178, P ¼ 0.385; for small LDL: r ¼ À0.086, P ¼ 0.674; and for very small LDL: r ¼ À0.101, P ¼ 0.624.
Discussion
The main effects of intervention with n-3 FA on lipoproteins were a reduction of VLDL size, reductions of the particle concentrations of large VLDL and small HDL and no significant effects on LDL subclasses. Importantly, we found that the effects on VLDL and HDL were induced without any obvious correlation with the reduction of insulin sensitivity (glucose utilization) by n-3 FA.
The validity of our findings seems strengthened by appropriate methods to measure insulin sensitivity and lipoprotein size and subclass concentrations, by a parallel design rather than a crossover one (the latter would entail problems with wash out and blinding), by good compliance, by stable dietary intake and by successful blinding. Further, the decision not to include subjects with marked hypertriglyceridemia should facilitate interpretations of results, as an effect of n-3-FA on hypertriglyceridemia could secondarily affect other lipoproteins (Harris, 1997) . It could be argued that the absence of overt hypertriglyceridemia in our subjects would make the results inapplicable for most subjects with type II diabetes. However, the median fasting concentration of triglycerides at baseline in this study (n ¼ 26) was 1.4 (0.6) mmol/l, which is comparable with that of the UKPDS study (Davis et al., 2005) . Hence, our results appear Table 2 , Mann-Whitney's test). P-values given in each plot are for time and treatment interaction based on log-transformed data, analyzed by repeated-measures ANOVA. Corn oil group (' .... '), n ¼ 14; fish oil group (m--m), n ¼ 12.
Effects of marine n-3 fatty acids on lipoprotein subclasses IL Mostad et al representative at least for a large segment of subjects with type II diabetes. The reductions of VLDL size and reduced concentration of large VLDL that we observed have, to our knowledge, not been previously reported. Others have reported no change in the distribution of VLDL subclasses in subjects with type II diabetes (Patti et al., 1999) or did not measure these subclasses (Petersen et al., 2002) . Reduction of VLDLcholesterol, on the other hand, is well documented but mainly in the setting of a concomitant lowering of triglycerides (Harris et al., 1983; Malasanos and Stacpoole, 1991; Connor, 2000; Montori et al., 2000) . In our nonhypertriglyceridemic subjects, we found treatment differences neither in the concentration of total VLDL particles nor in the concentration of triglycerides measured by standard methods or calculated from NMR measurements.
The effects of reductions that we observed in VLDL size and in the concentration of large VLDL in the fish oil group can be viewed as possibly antiatherogenic. Hence, an increment in VLDL size and in the concentration of large VLDL, has been associated with the state of type II diabetes (Garvey et al., 2003; Goff et al., 2005) . An increment in the concentration of large VLDL (as well as small HDL) has been suggested as a predictor of risk of atherosclerosis in general (Freedman et al., 1998) .
Our finding of decreased concentration of small HDL is also novel. Others have reported no effect of n-3 FA in subjects with type II diabetes (Luo et al., 1998) or a tendency to a smaller increase than in a control group (Petersen et al., 2002) . Reduction of small HDL was observed in one report, but this effect was seen only with intervention of EPA, not with DHA (Woodman et al., 2002) . In our case, the intervention included more DHA than EPA. As to the tendency to an increase in HDL size that we found, others have reported no such effect (Luo et al., 1998) or discrepant effects on the two subclasses of large HDL when measured by ultracentrifuging (HDL 2b increasing and HDL 2a slightly decreasing) (Table 3 Petersen et al., 2002) . However, Woodman et al. (2002) found a significant increase of large HDL in both EPA and DHA intervention groups, a result resembling ours of a tendency to an increase in the size of this possibly antiatherogenic lipoprotein subclass.
In contrast to the potentially antiatherogenic effects on VLDL and HDL, we found a tendency for an increase in the concentration of small LDL in our subjects with type II diabetes without hypertriglyceridemia. This finding is contrary to the reducing effect on small, dense LDL by marine n-3 FA reported in subjects with hypertriglyceridemia (Baumstark et al., 1992; Minihane et al., 2000; Wilkinson et al., 2005) . The presence or absence of hypertriglyceridemia could be an important factor for the effect of n-3 FA on small LDL as could the large intake of fish oil in our study, which resembles the one given to healthy subjects in which an increase in LDL apolipoprotein B was reported (Sullivan et al., 1986) .
In the present study, oxidized LDL did not show any tendency for an increase in the fish oil group. This finding might have been influenced by the intervention design, which, according to published data (Suzukawa et al., 1995; Nestel, 2000) , included enough vitamin E supplemented to avoid increased oxidizability of LDL.
As far as we know, this is the first study to compare shortterm and longer term intervention of n-3 FA on lipoprotein size and subclasses in subjects with type 2 diabetes. In general, effects were apparent already after 1 week of intervention. It is worthy of note that the effects on lipoprotein subclasses seemed to be parallel in time to previously presented changes in FA distribution in plasma phospholipids (Mostad et al., 2006) .
We are aware that lipoprotein subclasses are affected by changes in physical activity (Yu et al., 1999) and body weight ( Figure 5 , Mori et al., 1999) . To avoid such confounding, our subjects were instructed to avoid strenuous exercise the day before each testing and sampling day. Also, our subjects were weight stable throughout the study.
The baseline data of our study allow some comparisons with other populations of subjects with type II diabetes. The size and concentrations of lipoproteins at baseline were, in general, similar to those of a larger population of subjects (n ¼ 437) with type II diabetes . Exceptions were lower VLDL size and lower concentration of large VLDL in our study subjects, which could be explained by their nonelevated concentration of triglycerides. Further, our study subjects had a higher baseline concentration of large HDL.
Using the NMR technique Garvey et al. (2003) reported that insulin resistance was associated with a decrease in particle concentration of large HDL and an increase in small HDL and a cause-effect relationship was suggested. Causality, in obligatory terms, is, however, not supported by our results. Thus, we found that insulin sensitivity was reduced concomitant with reduction of large VLDL and small HDL particle concentrations and also with reduction of VLDL size. Discrepancies between effects on insulin sensitivity and effects on small HDL and VLDL size were also reported by Festa et al. (2005) . Thus, it seems clear that insulin sensitivity does not exert an overriding influence on particle concentration of large VLDL and small HDL, or on VLDL size.
The situation may be different with LDL. There is strong evidence for a causal connection between atherogenicity of LDL and insulin resistance (Garvey et al., 2003) . Such evidence is at least compatible with the tendency for negative effects on LDL subclasses in our study in the face of a moderate reduction of insulin sensitivity.
Some limitations of the present study should be mentioned. Power calculations were performed for measurements of insulin sensitivity (Mostad et al., 2006) and not specifically for testing intervention effects on lipoprotein subclasses. Also the NMR technique for measuring lipoprotein subclasses cannot a priori be extrapolated to size measurements obtained by gradient gel electrophoresis (Witte et al., 2004) . However, available studies do suggest a good correlation between the ultracentrifugation-based method and NMR in predicting a profile of a increased risk of cardiovascular disease (Petersen et al., 2005) .
Conclusions
In conclusion, in subjects with type II diabetes without hypertriglyceridemia a high intake of n-3 FA exerts several effects on lipoprotein size and subclass concentrations, some of which are potentially antiatherogenic. However, these effects are not coupled to n-3 FA-induced reduction of insulin sensitivity.
